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Background: Retrograde perfusion into coronary sinus during coronary artery bypass graft (CABG) surgery reduces
the need for cardioplegic interruptions and ensures the distribution of cardioplegia to stenosed vessel territories,
therefore enhancing the delivery of cardioplegia to the subendocardium. Peri-operative myocardial injury (PMI), as
measured by the rise of serum level of cardiac biomarkers, has been associated with short and long-term clinical
outcomes. We conducted a retrospective analysis to investigate whether the combination of antegrade and
retrograde techniques of cardioplegia delivery is associated with a reduced PMI than that observed with the
traditional methods of myocardial preservation.
Methods: Fifty-four consecutive patients underwent CABG surgery using either antegrade cold blood cardioplegia
(group 1, n = 28) or cross-clamp fibrillation (group 2, n = 16) or antegrade retrograde warm blood cardioplegia
(group 3, n = 10). The study primary end-point was PMI, evaluated with total area under the curve (AUC) of
high-sensitivity Troponin-T (hsTnT), measured pre-operatively and at 6, 12, 24, 48 and 72 hours post-surgery.
Secondary endpoints were acute kidney injury (AKI) and inotrope scores, length of intensive care unit (ICU) and
hospital stay, new onset atrial fibrillation (AF) and clinical outcomes at 6 weeks (death, non-fatal myocardial
infarction, coronary artery revascularization, stroke).
Results: There was evidence that mean total AUC of hsTnT was different among the three groups (P = 0.050).
In particular mean total AUC of hsTnT was significantly lower in group 3 compared to both group 1 (-16.55;
95% CI: -30.08, -3.01; P = 0.018) with slightly weaker evidence of a lower mean hsTnT in group 3 when
compared to group 2 (-15.13; 95% CI -29.87, -0.39; P = 0.044). There was no evidence of a difference when
comparing group 2 to group 1 (-1.42,; 95% CI: -12.95, 10.12, P = 0.806).
Conclusions: Our retrospective analysis suggests that, compared to traditional methods of myocardial preservation,
antegrade retrograde cardioplegia may reduce PMI in patients undergoing first time CABG surgery.
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The prompt delivery of cardioplegic solution to all regions
of the heart during cardiac surgery is essential for success-
ful myocardial protection [1]. PMI, detected through serial
measurements of specific serum biomarkers including
troponin I (TnI) or T (TnT) or creatine kinase (CK)-MB,
is associated with worse clinical outcomes [2-7].
Antegrade delivery of cardioplegic solution to myocar-
dial cells is adequate when supplied by unobstructed
coronary arteries but may not be equally effective in the
presence of occluded or stenosed arteries as in the case
of coronary artery disease (CAD), which may lead to
maldistribution of cardioplegic solution [8]. This might
induce PMI and poor recovery of left ventricular func-
tion (LV) following revascularization [9]. Limitations as-
sociated with antegrade delivery may be circumvented
by the administration of cardioplegic solution in a retro-
grade fashion through the coronary sinus which relies
on the principle that coronary venous systems free of
disease and valves can serve as a conduit for the delivery
of cardioplegic solution in a homogenous manner [10].
With this technique, the cardioplegic solution is distrib-
uted to the cardiac microstructure through a transmural
network of veins that is independent to flow-limiting le-
sions [11]. Nevertheless, retrograde cardioplegia pre-
sents important potential limitations, which could in
part explain the reason why its use remains still rela-
tively limited:
1) the anterior cardiac veins supplying the right
ventricle (RV) are not directly connected to the
coronary sinus and this may lead to a suboptimal
distribution of the cardioplegic solution to the
RV [12,13];
2) accurate cannulation of the coronary sinus is crucial
as failure in this might lead to the distribution of the
cardioplegic solution to the right atrium and not to
the venous system;
3) the perfusion pressure requires very close
monitoring, as too low a pressure suggests
misplacement of the cannula, and too high a
pressure can cause rupture of the coronary sinus
[14,15]. These potential issues can generally be
avoided by care and precision by the surgeon;
4) the delay in arresting the heart due to slow
retrograde perfusion if retrograde cardioplegia is
used alone (lower flow rates and pressures used to
prevent coronary sinus damage and myocardial
oedema) [16,17].
Therefore, the combination of both methods of ante-
grade and retrograde cardioplegia is thought to overcome
limitations inherent to both techniques [18]. However, al-
though both antegrade perfusion and retrograde coronarysinus perfusion have been studied experimentally and
used clinically in patients undergoing CABG surgery, there
is little information comparing PMI magnitude between
different methods of cardioprotection during revasculariza-
tion. In this regards, we conducted a retrospective subgroup
analysis to determine whether the combination of ante-
grade and retrograde cardioplegia is associated with im-
proved myocardial preservation in patients undergoing
CABG surgery.
Methods
Study design
We conducted a retrospective analysis of patients under-
going first time CABG surgery recruited between
December 2010 and July 2012 as a subgroup of control
patients in a large parallel single-blinded randomised
controlled clinical trial carried out at the Heart Hospital,
University College London Hospital (London, UK), and
investigating the effects of remote ischaemic precondi-
tioning (RIPC) [4,5] in patients undergoing cardiac sur-
gery. The surgery was carried out in accordance with the
University College London Hospital NHS Trust guide-
lines and received local Ethics Committee approval. We
obtained written informed consent from all patients
recruited into the study.
Inclusion and exclusion criteria
Patients included in the current analysis were recruited
within a single centre study investigating the effects of
RIPC [19,20] in patients undergoing CABG surgery at
the Heart Hospital (UCLH London, UK): only patients
receiving the control protocol were included.
Patient exclusion criteria comprised:
a) cardiogenic shock or cardiac arrest preceding
surgery;
b) positive baseline serum hsTnT;
c) pregnancy;
d) significant peripheral arterial disease (PAD) affecting
upper and/or lower limbs;
e) significant hepatic dysfunction (International
Normalised Ratio > 2.0);
f ) significant pulmonary disease (Forced Expiratory
Volume-1 < 40% predicted);
g) renal failure with an estimated glomerular filtration
rate <30 mL/min/1.73 m2;
h) concomitant therapy with glibenclamide or
nicorandil, as these medications have been
demonstrated to potentially interfere with RIPC.
Surgical procedure
Temazepam 10-20 mg was given one hour prior to
surgery. Anaesthesia induction was obtained under
cardiac monitoring with combinations of midazolam,
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(rocuronium, vecuronium or pancuronium). Endo-
tracheal intubation was achieved and mechanical venti-
lation commenced with oxygen with or without air. For
anaesthesia maintenance volatile anaesthetic agents and
propofol infusion with or without fentanyl were used.
Continuous monitoring of arterial blood pressure, cen-
tral venous pressure, nasopharyngeal temperature was
carried out.
Standard non-pulsatile cardiopulmonary bypass (CPB)
was initiated with the use of membrane oxygenator and
cardiotomy suction, followed by the construction of all
coronary artery bypass grafts, using either blood cardio-
plegia or intermittent cross-clamp fibrillation.
Group 1 had 1 litre of cold blood cardioplegia given
once the cross clamp was placed and maintenance cold
blood cardioplegia was given down the grafts in oc-
cluded arteries and also into the aortic root every 20-30
minutes.
Group 2 had coronary artery surgery with the cross
clamp fibrillation technique and therefore no cardiople-
gic solution was given.
Group 3 had warm blood cardioplegia delivered with
antegrade and retrograde techniques and was per-
formed by one cardiothoracic surgeon, with an initial
800 ml dose of antegrade cardioplegia followed by
400 ml of retrograde cardioplegia. After this, mainten-
ance was achieved with 100 ml of retrograde cardiople-
gia after each anastamosis. A hot shot of warm blood
without potassium was given after the internal mam-
mary artery (IMA) anastamosis and prior to removal of
the cross clamp. All anastomoses were constructed with
the single clamp technique. Systemic temperature in
group 3 was 35°C.
Following anastomosis of the grafts, CPB was discontin-
ued and protamine was used to achieve heparin reversal.
Objectives
To determine whether the addition of retrograde cardio-
plegia to standard antegrade cardioplegia can reduce
PMI and subsequently improve short-term clinical out-
comes in patients undergoing first time CABG surgery
compared to patients receiving either standard antegrade
cardioplegia alone or cross-clamp fibrillation.
Study endpoints
The primary study end-point was PMI, measured by total
72 hour AUC of hsTnT. Blood samples for hsTnT were
taken pre-operatively and at 6, 12, 24, 48 and 72 hours
post-surgery; hsTnT was measured quantitatively by a
one-step enzyme immunoassay based on electrochemilu-
minescence technology (Roche, Switzerland). The lower
detection limit of this assay is 1 ng/L with a threshold
of ≥14 ng/L indicating significant myocardial necrosis.Secondary end-points included:
1. AKI score, classified as grade 1, 2 or 3 based on a
combination of laboratory (serum creatinine levels)
and clinical (urine output) parameters [21]. Serum
creatinine was measured pre-operatively and 24, 48
and 72 hours post-surgery.
2. Inotrope requirement during the first 3 post-operative
days, measured using the formula modified from a
study by Ko et al. [22]: Inotrope score = Dosages
(μg/kg/min) of:
3. Length of ICU and hospital stay;
4. New onset of AF in the three post-operative days;
5. Clinical outcomes at 6 weeks (death, non-fatal
myocardial infarction, coronary artery
revascularization, stroke).
Statistical analysis
Continouos data are presented as mean (standard devi-
ation (SD)) or median (IQR). Categorical data are shown
as number (percent). The exposure variable was a categor-
ical variable with three groups corresponding to each of
the cardioprotection categories. Comparison between ex-
posure groups was made by including the exposure vari-
able as a categorical variable in a linear regression model
for approximately normally distributed endpoint variables.
For very skewed endpoint variables the median T-test was
used. Where continuous endpoint variables were mea-
sured over time a repeated measures linear regression
model was fitted to measure the association between
exposure variable and endpoint. The assumptions of the
linear regression models were performed by analysis of
residuals. Categorical data were analysed using Fisher’s
exact test. No adjustment for multiplicity has been made.
Data were analysed using Stata version 12.1.
Results
Included patients were recruited into an original RIPC
trial enrolling a total of 180 subjects of which 90 patients
were randomised to control: 36 patients were subse-
quently excluded (1 patient died intra-operatively and the
remaining 35 underwent CABG and valve surgery or valve
surgery alone). Therefore we ultimately analysed data for
54 patients undergoing CABG surgery alone: 28 received
antegrade cold blood cardioplegia (group 1), 16 patients
received cross-clamp fibrillation (group 2) and 10 ante-
grade retrograde warm blood cardioplegia (group 3).
Group 3 had a lower rate of positive family history of
CAD and previous percutaneous coronary intervention
(p = 0.047) whereas group 3 had a higher incidence of
cerebro-vascular accidents prior to CABG surgery (p =
0.025, Table 1): no other significant difference was found
among the three groups with respect to baseline patient
baseline characteristics (Table 1). Expectedly, cross-
Table 1 Patient baseline characteristics
Patients Group 1 Group 2 Group 3
Antegrade cardioplegia Cross-clamp fibrillation Antegrade retrograde cardioplegia
(n = 28) (n = 16) (n = 10)
Age 67 ± 8 62 ± 10 69 ± 9
Gender
Male 23 (82%) 12 (75%) 8 (80%)
Female 5 (18%) 4 (25%) 2 (20%)
Ethnicity
Caucasian 21 (75%) 13 (81%) 9 (90%)
Afro-Caribbean 1 (4%) 1 (6%) 1 (10%)
Asian 5 (18%) 2 (13%) 0 (0%)
Chinese 1 (4%) 0 (0%) 0 (0%)
BMI 27.6 ± 4.9 30.4 ± 5.0 27.8 ± 4.5
SBP (mmHg) 131.3 ± 20.8 128.3 ± 16.9 128.9 ± 21.2
DBP (mmHg) 70.3 ± 7.4 73.4 ± 10.6 69.1 ± 11.6
HR (bpm) 66.8 ± 11.1 68.6 ± 10.5 65.7 ± 13.9
Smoking history
Smoker 4 (14%) 4 (25%) 1 (10%)
Non-smoker 6 (21%) 4 (25%) 4 (40%)
Ex-smoker 18 (64%) 8 (50%) 5 (50%)
Family history of IHD 22 (79%) 13 (81%) 4 (40%)
NYHA class
0 2 (7%) 3 (21%) 2 (22%)
I 8 (29%) 5 (34%) 4 (44%)
II 17 (61%) 5 (34%) 2 (22%)
III 1 (4%) 1 (7%) 1 (11%)
IV 0 (0%) 0 (0%) 0 (0%)
CCS Class
0 5 (18%) 2 (14%) 3 (33%)
I 4 (14%) 5 (36%) 0 (0%)
II 16 (57%) 6 (43%) 4 (44%)
III 2 (7%) 1 (7%) 1 (11%)
IV 1 (4%) 0 (0%) 1 (11%)
LVEF
>50% 19 (68%) 12 (75%) 7 (70%)
30%-50% 8 (29%) 3 (19%) 3 (30%)
<30% 1 (4%) 1 (6%) 0 (0%)
Co-morbidities
Diabetes mellitus 11 (39%) 6 (38%) 0 (0%)
Hypertension 25 (89%) 13 (81%) 7 (70%)
Hypercholesterolemia 25 (89%) 15 (94%) 8 (80%)
Atrial fibrillation 3 (11%) 0 (0.0%) 2 (20%)
Previous MI 13 (47%) 3 (19%) 6 (60%)
Previous PCI 8 (29%) 1 (6%) 0 (0%)
Previous CVA/TIA 3 (11%) 0 (0%) 3 (30%)
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Previous cardiac surgery 0 (0%) 0 (0%) 0 (0%)
Peripheral arterial disease 3 (11%) 1 (6%) 2 (20%)
Drug history
Aspirin 3 (11%) 2 (14%) 0 (0%)
Clopidogrel/Prasugrel 2 (7%) 0 (0%) 0 (0%)
Warfarin 1 (4%) 0 (0%) 0 (0%)
Beta-blocker 22 (79%) 11 (79%) 8 (80%)
Calcium channel blocker 12 (43%) 3 (21%) 4 (40%
Statin 26 (93%) 13 (93%) 10 (100%)
ACE-I/ARB 20 (71%) 8 (57%) 6 (60%)
Long acting nitrates 7 (25%) 2 (14%) 3 (30%)
Antidiabetics
Insulin 4 (14%) 2 (14%) 0 (0%)
Biguanide 2 (7%) 1 (7%) 0 (0%)
Sulphonylurea 5 (18%) 2 (14%) 0 (0%)
Diuretics 7 (25%) 4 (29%) 2 (20% )
Indication for surgery
Angina 23 (82%) 13 (81%) 7 (70%)
Myocardial infarction 5 (18%) 3 (19%) 3 (30%)
EuroSCORE 3.2 ± 1.9 2.7 ± 1.7 3.8 ± 1.8
Additive perioperative risk
Low (EuroSCORE 0-2) 13 (46%) 8 (50%) 1 (10%)
Medium (EuroSCORE 3-5) 12 (43%) 7 (44%) 7 (70%)
High (EuroSCORE >5) 3 (11%) 1 (6%) 2 (20%)
Bypass-time (min) 93.9 ± 34.6 77.2 ± 22.0 80.3 ± 12.8
Cross-clamp time (min) 62.2 ± 24.4 33.0 ± 7.5 63.7 ± 13.4
Number of grafts
One 1 (4%) 0 (0.0%) 0 (0.0%)
Two 9 (32%) 3 (19%) 1 (10.0%)
Three 10 (36%) 10 (63%) 8 (80.0%)
Four 8 (29%) 3 (19%) 1 (10.0%)
Anesthetic agents
Induction
Anti-nicotinic agents
Rocuronium 24 (86%) 12 (92%) 6 (60%)
Pancuronium 3 (11%) 1 (7%) 2 (22%)
Vecuronium 1 (4%) 0 (0.0%) 1 (11%)
Midazolam 12 (43%) 7 (54%) 6 (67%)
Etomidate 1 (4%) 2 (14%) 2 (22%)
Fentanyl 28 (100%) 14 (100%) 9 (100%)
Propofol 27 (96%) 12 (86%) 7 (78%)
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Maintenance
Propofol 28 (100%) 14 (100%) 9 (100%)
Volatile anesthetics
Isoflurane 25 (89%) 13 (93%) 9 (100.%)
Sevoflurane 3 (11%) 1 (7%) 0 (0.0%)
Intra-operative GTN 24 (89%) 14 (86%) 8 (89%)
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; IHD = ischaemic heart disease; NYHA = New York Health
Association; CCS = Canadian Cardiovascular Society; LVEF = left ventricular ejection fraction; MI = Myocardial infarction; PCI = Percutaneous coronary intervention;
CVA = Cerebrovascular accident; TIA = Transient ischaemic attack; ACE-I = Angiotensin-converting enzyme inhibitor; ARB = Angiotensin receptor blocker; GTN =
glyceryl trinitrate.
The following parameters have missing values: BMI (Group-2 2), SBP (Group-2 2), DBP (Group-2 2) HR (Group-2 2), Cardio-pulmonary bypass time time (Group-2 2),
Cross-clamp time (Group-2 3), NYHA (Group-2 2, Group-3 1), CSS (Group-2 2, Group-3 1), Aspirin (Group-2 2), Clopidogrel (Group- 2), Warfarin (Group-2 2), Beta-blockers
(Group-2 2), Calcium-channel blockers (Group-2 2), Long-acting (Group-2 2), Statins (Group-2 2), ACE-I/ARB (Group-2 2), Insulin (Group-2 2), Sulphonylurea (Group-2 2),
Biguanide (Group-2 2), Diuretics (Group-2 2), Anti-nicotinic agents (Group-2 3, Group-3 1), Midazolam (Group-2 3, Group-3 1), Etomidate (Group-2 2, Group-3 1),
Fentanyl-induction (Group-2 2, Group-3 1), Proprofol-induction (Group-2 2, Group-3 1), Proprofol-maintanance (Group-2 2, Group-3 1), Volatile anaesthetics (Group-2 2,
Group-3 1), Intra-operative GTN (Group-3 1).
Significance difference: Family history of IHD: p = 0.041; Previous PCI: p = 0.047, Previous CVA/TIA: p = 0.025, Cross-clamp time: p = <0.001.
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0.001), however all the remaining parameters of surgery
were similar amongst the 3 groups (Table 1).
Primary endpoint
Overall there was evidence that the mean total 72 hr
AUC hsTnT was different among the three groups (P =
0.050). Examining the subgroup differences showed evi-
dence of lower mean hsTnT in group 3 compared to group
1 (-16.55; 95% CI: -30.08, -3.01; P = 0.018) with slightly
weaker evidence of a lower mean hsTnT in group 3 when
compared to group 2 (-15.13,; 95% CI -29.87, -0.39; P =
0.044). There was no evidence of a difference when com-
paring group 2 to group 1 (-1.42,; 95% CI: -12.95, 10.12,
P = 0.806) (Figure 1, Table 2).
Secondary endpoints
Baseline pre-operative hsTnT levels were <0.02 μg/L and
not significantly different between the 3 groups (Figure 2,Figure 1 Mean hsTnT pre-operatively and at 6, 12, 24, 48 and 72 houTable 2). Overall there was evidence that the mean hsTnT
differed at 6 hours (P < 0.001) and 12 hours (P < 0.001). At
6 hours there was evidence that mean hsTnT was lower
in group 3 than groups 1 (-0.56; 95% CI: -0.78, -0.34).
Similarly at 12 hours there was some evidence that
mean hsTnT was lower in group 3 than group 1 (-0.43,
95% CI: -0.65, -0.21) (Figure 2, Table 2).
There was no evidence of a significant difference
among the three groups with regards to each of the sec-
ondary endpoints (Table 3).Discussion
Myocardial preservation during cardiac surgery is cer-
tainly one of the most debated topics in this field. One
method of achieving myocardial protection is by using a
cardioplegic solution administered into the heart to
achieve a temporary arrest of the myocardium whilst the
surgeon performs the operation in a bloodless field.rs post-surgery in the three study groups.
Table 2 Total hsTnT release and mean hsTnT at the 6 time-points
Patients Group 1 Group 2 Group 3 Comparison Difference Sub-group
Antegrade
cardioplegia
Cross-clamp
fibrillation
Antegrade retrograde
cardioplegia
Group (95% CI) P value
(n = 28) (n = 16) (n = 10)
(Mean [SD]) (Mean [SD]) (Mean [SD])
Total 72 hours AUC 34.304 (20.352) 32.885 (18.771) 17.756 (7.542) P = 0.050 1 vs 2 −1.419 (-12.954, 10.115) 0.806
1 vs 3 −16.548 (-30.082, -3.014) 0.018
2 vs 3 −15.129 (-29.867, -0.390) 0.044
Pre-operatively 0.021 (0.020) 0.022 (0.022) 0.014 (0.012) P = 0.997 1 vs 2 0.000 (-0.188, 0.188)
1 vs 3 −0.008 (-0.229, 0.213)
2 vs 3 −0.008 (-0.250, 0.234)
6 hours post-operatively 0.961 (0.619) 0.696 (0.235) 0.399 (0.117) P < 0.001 1 vs 2 −0.265 (-0.453, -0.077)
1 vs 3 −0.562 (-0.783, -0.341)
2 vs 3 −0.297 (-0.539, -0.055)
12 hours post-
operatively
0.752 (0.494) 0.631 (0.195) 0.319 (0.112) P < 0.001 1 vs 2 −0.121 (-0.309, 0.067)
1 vs 3 −0.433 (-0.654, -0.212)312
2 vs 3 (-0.557, -0.070)
24 hours post-
operatively
0.508 (0.309) 0.476 (0.305) 0.266 (0.134) P = 0.100 1 vs 2 −0.032 (-0.220, 0.156)
1 vs 3 −0.241 (-0.463, -0.020)
2 vs 3 −0.209 (-0.451, 0.033)
48 hous post-operatively 0.359 (0.224) 0.410 (0.339) 0.227 (0.114) P = 0.335 1 vs 2 0.044 (-0.144, 0.233)
1 vs 3 −0.139 (-0.360, 0.083)
2 vs 3 −0.183 (-0.425, 0.059)
72 hours post-
operatively
0.347 (0.231) 0.381 (0.271) 0.186 (0.119) P = 0.257 1 vs 2 0.027 (-0.161, 0.216)
1 vs 3 −0.168 (-0.390, 0.054)
2 vs 3 −0.195 (-0.437, 0.047)
SD = standard deviation; hsTnT = high sensitivity Troponin T; AUC = Area under the curve.
The following secondary endpoints had missing values: hsTnT 48 hours post-operatively (Group-1 1), hsTnT 72 hours post-operatively (Group-1 1), AUC (Group-1 1).
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are used, including cold blood antegrade cardioplegia
with topical cooling, warm blood antegrade cardioplegia,
warm blood antegrade and retrograde cardioplegia, cold
blood antegrade and retrograde cardioplegia and cross
clamp fibrillation.
In current practice the route of delivery is at the sur-
geon’s discretion and as such there is no consensus on
using a specific route to supply the cardioplegia into the
myocardium.
The most common technique used by the majority of
cardiac surgeons is the antegrade route, in which cardio-
plegia is delivered into the aortic root and spreads via the
coronary arteries supplying the myocardium. Although
significant clinical evidence favours the safety of this
method, severe stenoses of coronary arteries in patients
undergoing CABG may prevent the uniform distribution
of cardioplegic solution through the myocardium [23]
and, importantly, sub-optimal or inadequate distribution
to parts of the myocardium increases the risk for PMI.A proposed solution to overcome this limitation is the
retrograde route of delivery, in which cardioplegia is ad-
ministered through the coronary sinus and through the
extensive venous network of the myocardium. Following
the pioneering idea of Pratts [24] who suggested that an
ischemic myocardium could be revived back into its
healthy form by supplying oxygenated blood through the
veins, retrograde cardioplegia was applied for the first time
by Blanco et al. [25] in 1956 and further developed in a
significant number of centres: one of the seminal works
on retrograde cardioplegia was conducted by Menasche
et al. [26] who demonstrated that, during aortic valve re-
placement (AVR) surgery, post-operative haemodynamic
stability, cardiac outputs and right and left ventricular
stroke indices were similar in patients receiving retro-
grade cardioplegia compared to those receiving ante-
grade cardioplegia. The same authors also conducted a
retrospective observational study on a relatively large
group of patients undergoing isolated AVR or CABG
surgery with or without concomitant valve surgery
Figure 2 AUC of hsTnT over the 72 hours post-surgery in the
three study groups.
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there was no antegrade cardioplegia group for direct
comparison, they reported that the overall trend in mor-
tality rates was either similar or less than what other
studies had shown.
With the knowledge that the anterior cardiac veins sup-
plying the RV are not directly connected to the coronary
sinus and thus may lead to a suboptimal distribution of
the cardioplegic solution to the RV [12,13] Kaukoranta
et al. [28] conducted a small study on patients undergoing
CABG surgery and receiving either antegrade or retro-
grade cardioplegia and reported that, despite more signifi-
cant ischaemic changes within the RV in the retrograde
cardioplegia group, no post-operative complication related
to the retrograde route was observed.
It is therefore clear from the literature that multifactorial
clinical endpoints have been used to determine a difference
between myocardial protection strategies: moreover the
population size in these studies was often too small to
come to a meaningful conclusion on the benefit of a par-
ticular protection strategy. Importantly, many of the stud-
ies on retrograde cardioplegia used retrograde cardioplegia
alone when compared to antegrade cardioplegia and only
very few studies have compared the combination of ante-
grade and retrograde techniques against antegrade cardio-
plegia alone: this is one more reason to interpret current
literature with caution.
In the only other study similar to our retrospective
analysis, Radmehr and his colleagues [13] compared the
combined antegrade and retrograde versus antegrade
cardioplegia alone in patients undergoing CABG surgery
and found that the use of combined antegrade and retro-
grade cardioplegia was associated with a 16.5% statisti-
cally significant decrease in inotropic requirement.Our retrospective study suggests that myocardial protec-
tion can be improved by combined antegrade and retro-
grade technique and, in contrast to literature already
available, our patient cohort is divided into three groups
(the combined technique of antegrade and retrograde car-
dioplegia, antegrade cardioplegia alone and cross-clamp
fibrillation). We only included patients undergoing CABG
surgery and excluded subjects undergoing either valve sur-
gery alone or CABG combined with valve surgery. This
enabled us to assess the drawbacks of the antegrade tech-
nique via blocked coronaries and therefore the potential
benefit of retrograde cardioplegia.
In addition to this, with an increase in the cross-clamp
time the general understanding is that the myocardium
is more prone to becoming ischaemic and damaged: our
study suggests that despite longer cross-clamping times
in the combined group, the total PMI was consistently
lower in these patients when compared to the other
two groups. This correlates with a retrospective study
conducted by Bar-El et al. [29] on patients undergoing
CABG surgery with or without valve repair or replace-
ment and receiving antegrade followed by retrograde
cardioplegia, demonstrating that the expected mortality
was lower in patients with longer aortic cross-clamping
times compared to those with shorter aortic cross-
clamping times, and therefore indicating that retrograde
cardioplegia can enhance myocardial protection despite
the longer cross-clamp times. We therefore suggest that
the absolute value of the cross-clamp time may poten-
tially be less important than the type of myocardial pro-
tection used: this could be crucial in complex patients
with poor LV function or anticipated long cross-clamp
times, for whom the best myocardial protection available
would be warranted.
Another important difference between groups 1 and 3
is the temperature employed during the cardioplegic
techniques utilizing cold blood and warm blood cardio-
plegia respectively: the optimal temperature of cardiople-
gia during cardiac surgery is another crucial aspect of
myocardial protection besides the actual technique used
and it could be argued that the lower troponin rise in
group 3 may be partially explained by the temperature
difference. Cold cardioplegia is able to attenuate myocar-
dial oxygen demand and the risk of ischaemic damage
but conversely may lead to the inhibition of myocardial
enzymes leading to a stunning of the metabolic and func-
tional recovery following surgery. However warm blood
cardioplegia is thought to counteract this potential
deleterious effect. In a meta-analysis [30] involving 8814
patients randomised to either warm cardioplegia or cold
cardioplegia predominantly in the setting of CABG sur-
gery, there was no significant difference in all-cause mor-
tality or incidence of myocardial infarction, intra-aortic
balloon pump usage, stroke, low output syndromes and
Table 3 Summary of study secondary endpoints
Patients Group 1 Group 2 Group 3 P value
Antegrade cardioplegia Cross-clamp fibrillation Antegrade retrograde cardioplegia
(n = 28) (n = 16) (n = 10)
(Mean [SD]) (Mean [SD]) (Mean [SD])
AKI (N)
0 22 (79%) 11 (69%) 10 (100.0%)
1 5 (18%) 2 (13%) (0.0%)
2 0 (0.0%) 2 (13%) (0.0%)
3 1 (4%) 1 (6%) (0.0%)
Total number of AKI cases 6 (21%) 5 (31%) 0 (0.0%) 0.281*
Inotrope score (mg/kg/hr)
Post bypass 7.24 (13.79) 4.03 (11.92) 3.76 (4.35) 0.816**
24 hours post-operatively 11.90 (21.32) 10.11 (22.88) 3.67 (4.36) 0.635**
48 hours post-operatively 8.76 (15.39) 14.93 (33.57) 1.94 (2.98) 0.101**
72 hours post-operatively 1.85 (5.30) 13.54 (33.13) 2.13 (2.95) 0.015**
Total 29.88 (49.10) 42.54 (94.66) 11.66 (13.79) 0.545***
New onset AF (N) 6 (21%) 5 (31%) 4 (40.0%) 0.475*
Length of ICU stay (days) 2.0 (2.0-4.0)**** 3 (1.0-7.5)**** 2.0 (1.0-3.0)**** 0.802*****
Length of hospital stay (days) 8.5 (7.0-11.50)**** 8.0 (6.0-10.50)**** 7.5 (6.0-9.00)**** 0.523*****
Clinical outcomes at 6 weeks (N)
Death 3 (14%) 0 (0.0%) 0 (0.0%) 0.283*
Myocardial infarction 1 (4%) 0 (0.0%) 0 (0.0%) 1.000*
Stroke 0 (0.0%) 0 (0.0%) 0 (0.0%) 1.000
Revascularization 0 (0.0%) 0 (0.0%) 0 (0.0%) 1.000*
SD = standard deviation AKI = Acute Kidney Injury; AF = atrial fibrillation; ICU = Intensive Care Unit.
*P value for Fisher’s exact test.
**P-value from repeated measures linear regression model.
***P-value form linear regression model.
****Results shown as median (inter-quartile range).
*****P-value for Median T test.
The following secondary endpoints had missing values: Inotrope Score post-bypass (Group-1 2, Group-2 2, Group-3 1), Inotrope Score 24 hours post-operatively
(Group-1 3, Group-2 2, Group-3 1), Inotrope Score 48 hours post-operatively (Group-1 3, Group-2 2, Group-3 2), Inotrope Score 72 hours post-operatively (Group-1 3,
Group-2 2, Group-3 2), Inotrope Score Total (Group-1 3 , Group-2 2, Group-3 2), Length of ICU stay (Group-2 1), Length of Hospital stay (Group-2 1), Death (Group-1 7,
Group-2 3, Group-3 2), Myocardial Infarction (Group-1 7, Group-2 3, Group-3 2), Stroke (Group-1 7, Group-2 3, Group-3 2), Revascularization (Group-1 7, Group-2 3, Group-3 2).
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postoperative cardiac index was significantly improved in
the warm blood cardioplegia group. Similarly, Tan et al.
[31] compared cold to tepid cardioplegia and found no dif-
ference in mortality, peri-operative myocardial infarction,
stroke or inotrope requirement.
Our retrospective study has several limitations. The co-
hort population was small and in particular the group con-
sisting of the combined use of retrograde cardioplegia and
antegrade cardioplegia contained only 10 patients, who
were operated on by one consultant, which may result in
some potential bias. Typically in a study of this type strong
prognostic and confounding variables would be adjusted
for in the analysis. In this case the small sample size pre-
cluded detailed adjustment and we acknowledge some
residual confounding bias may remain. Finally, we have
not adjusted for multiplicity in our analysis and there is apossibility that the results may have arisen by chance, and
therefore the clinical outcome data will need to be con-
firmed in future studies.
In conclusion our retrospective clinical analysis suggests
that the combined use of retrograde cardioplegia and
antegrade cardioplegia during first time CABG surgery
can be beneficial in reducing PMI. Also, importantly, to
our knowledge there is no study which combines the fol-
lowing four factors together into one analysis on PMI: aor-
tic cross-clamping times, combined antegrade retrograde
versus antegrade alone versus no cardioplegia, hsTnT
levels at 6 different time-points with AUC-hsTnT, and ex-
clusively CABG patients. We do not suggest surgeons to
change their practice for routine CABG surgery, as we
have not yet demonstrated that the change in measured
troponin levels may have a significant impact on clinical
outcomes. However, we feel that this evidence should be
Candilio et al. Journal of Cardiothoracic Surgery  (2014) 9:184 Page 10 of 11available, so surgeons can choose to add retrograde cardi-
oplegia for more complex cases in an evidence based fash-
ion, knowing that the addition of retrograde cardioplegia
may have the potential to enhance myocardial protection.
Our retrospective study also suggests that larger studies
are required in order to further evaluate our findings and
to investigate whether the reduction of PMI in patients
undergoing CABG would result in improvement of clin-
ical outcomes.
Conclusions
Our study suggests that, compared to traditional methods
of myocardial preservation, the combined use of retro-
grade and antegrade cardioplegia may have the potential
to reduce PMI in patients undergoing first-time CABG
surgery. Whether this can lead to an improvement of clin-
ical outcomes is yet unknown and therefore larger studies
are required in order to further evaluate this potential
impact.
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